337 related articles for article (PubMed ID: 15478206)
1. Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Manyam BV; Dhanasekaran M; Hare TA
Phytother Res; 2004 Sep; 18(9):706-12. PubMed ID: 15478206
[TBL] [Abstract][Full Text] [Related]
2. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters.
Manyam BV; Dhanasekaran M; Hare TA
Phytother Res; 2004 Feb; 18(2):97-101. PubMed ID: 15022157
[TBL] [Abstract][Full Text] [Related]
3. Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity.
Dhanasekaran M; Tharakan B; Manyam BV
Phytother Res; 2008 Jan; 22(1):6-11. PubMed ID: 18064727
[TBL] [Abstract][Full Text] [Related]
4. Anti-Parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage.
Tharakan B; Dhanasekaran M; Mize-Berge J; Manyam BV
Phytother Res; 2007 Dec; 21(12):1124-6. PubMed ID: 17622977
[TBL] [Abstract][Full Text] [Related]
5. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease.
Shim JS; Kim HG; Ju MS; Choi JG; Jeong SY; Oh MS
J Ethnopharmacol; 2009 Nov; 126(2):361-5. PubMed ID: 19703534
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-Reduced
Johnson SL; Park HY; DaSilva NA; Vattem DA; Ma H; Seeram NP
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30131460
[No Abstract] [Full Text] [Related]
7. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
8. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
Bilbao G; Ruiz-Ortega JA; Miguens N; Ulibarri I; Linazasoro G; Gómez-Urquijo S; Garibi J; Ugedo L
Brain Res; 2006 Apr; 1084(1):175-84. PubMed ID: 16574080
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
Jin F; Wu Q; Lu YF; Gong QH; Shi JS
Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
[TBL] [Abstract][Full Text] [Related]
11. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Crotty S; Fitzgerald P; Tuohy E; Harris DM; Fisher A; Mandel A; Bolton AE; Sullivan AM; Nolan Y
Eur J Neurosci; 2008 Jan; 27(2):294-300. PubMed ID: 18190522
[TBL] [Abstract][Full Text] [Related]
14. Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Cilia R; Laguna J; Cassani E; Cereda E; Raspini B; Barichella M; Pezzoli G
Parkinsonism Relat Disord; 2018 Apr; 49():60-66. PubMed ID: 29352722
[TBL] [Abstract][Full Text] [Related]
15. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
[TBL] [Abstract][Full Text] [Related]
16. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G
J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B
Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
19. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity.
Przedborski S; Jackson-Lewis V; Muthane U; Jiang H; Ferreira M; Naini AB; Fahn S
Ann Neurol; 1993 Nov; 34(5):715-23. PubMed ID: 8239566
[TBL] [Abstract][Full Text] [Related]
20. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
Li LY; Zhao XL; Fei XF; Gu ZL; Qin ZH; Liang ZQ
Acta Pharmacol Sin; 2008 May; 29(5):539-47. PubMed ID: 18430361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]